



Received: 3. November 2010
Accepted: 26. January 2011.
Take The besT – how To choose The righT 
device?
stephan w. hirt, christof schmid
department of cardiothoracic surgery, University Medical centre, regensburg, 
germany
Summary
An increasing number of patients suffering from end-stage heart failure require VAD 
implantation as either a bridge-to-transplantation or destination therapy. The choice of 
the right device depends upon the medical urgency; the need of uni- or biventricular 
support; the duration of support expected; and the institutional availability. Patients 
with multi-organ failure and unclear neurological situation can be supported with rotary 
pumps/ECMO first, and in case of recovery, a paracorporeal system can be connected 
to the previously implanted cannulas. In stable patients qualifying for left ventricular 
support, an intracorporeal system of the second generation can be implanted, allowing 
freedom of movement for 6-8 hours before recharging becomes necessary, and support 
intervals exceeding 1 year. Restrictions are given by the need of high-dose anticoagula-
tion and a certain complication rate, especially in the first 3 months (bleeding, throm-
boembolism, infection, mechanical failure). The survival rate after the primary LVAD 
implantation is 74 % after 12 months and 55 % after 24 months; this is significantly 
better than the survival rate after RVAD, BVAD or TAH.
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considering cardiac support, the selection of the best device for individual pa-
tients in their particular situations is a major challenge, besides technical issues 
and postoperative management. This is especially the case if long-term support is 
required. The patients’ outcome after the implantation of a ventricular assist device 
(VAD) is affected by their health status, including medical urgency, the need for ino-
tropes, the extending of end-organ failure, the right ventricle function, coagulation 
disorders, the suspicion of infection, severe myocardial necrosis, and previous car-
diac surgery. Elective patients suffering from chronic heart failure without myocar-
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dial necrosis, with no or low-dose inotropic support and intact end-organ function, 
are at low risk. Patients in acute low cardiac output following myocardial infarction, 
resuscitation or cardiac surgery, requiring high doses of inotropes and with immi-
nent multi-organ failure (MOF) are exposed to high risk after a VAD implantation. 
One of the most critical factors for implant success, however, is the age. According 
to deng et al. (J heart Lung Transplantation 2005), 41 % of patients ≤ 65 years were 
still alive 12 months after a VAD implantation, while 20 % had undergone heart 
transplantation. in contrast, the one-year survival rate of vad patients > 65 years 
was only 26 %, and none of these patients had a transplant option. 
Nowadays, a variety of VADs are commercially available. They are categorized 
into extra-/ paracorporeal devices (ECMO, Excor, ThoratecPVAD, Medos, Abiomed), 
intracorporeal systems and fully implantable total artificial hearts (Cardiowest TAH). 
The intracorporeal systems of the first generation were large displacement pumps 
(Novacor, Heartmate I), followed by the second-generation impeller pumps (Incor, 
Heartmate II, DeBakey LVAD, Jarvik Heart). The centrifugal technique (Heartware, 
Terumo, Coraid) is yet to be established on the market.
For device selection, several issues have to be considered. in many institutions, 
the costs determine the availability and the spectrum of mechanical support sys-
tems. A special expertise with one or the other device improves the results, but also 
influences the support strategies. Eventually, the device selection is based on the 
clinical setting to optimise the resources. Most patients are provided with a left-ven-
tricular assist device (Lvad). due to the inability of the current allocation system 
to provide donor hearts in time, and the consequently longer waiting periods, there 
is a clear trend towards the use of implantable systems. In the US, the Heartmate II 
device has the most widespread use, whereas in Europe and Asia, the BerlinHeart 
Incor is equally favoured. It may well be that all miniaturized LVADs serve the 
same purpose alike, provided that the implant team has the necessary expertise. 
The impeller devices have a low weight, allowing 5,000-10,000 rotations per minute, 
and generate the pump flow up to 6 l/minute. The INCOR system operates without 
any mechanical contact and ensures a wear-free long-term support for patients with 
terminal heart failure. A driveline is connected to a double-battery power pack, al-
lowing the system to operate for 6-8 hours before recharging becomes necessary. 
during the past years, the number of implantations has dramatically increased, and 
the support intervals exceeding one year are no longer an exception.
Paracorporeal devices were primarily designed for biventricular use, i.e. for 
combined left and right heart failure. In fact, there is still no implantable biventricu-
lar rotary pump available today. another suitable indication for paracorporeal sys-
tems are patients with multi-organ failure, as they demand higher pump flows than 
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urgent cases. A third indication is a borderline patient with a high risk of failure, 
who compromises the clinical budgets. Especially for the latter cases, new strate-
gies have been developed to optimise the financial resources. Patients presenting 
with unclear neurology in an emergency situation are placed on ECMO first, for a 
short-term support as a bridge-to-decision. if recovery from MoF is doubtful but 
the patient is awake, two rotary pumps may be used as well. After the stabilisation 
of end-organ function, the rotary pumps/ecMo are converted to a biventricular 
assist device (BVAD). To simplify the conversion, we recommend the use of four 
implantable cannulas (right atrium / pulmonary artery; left ventricular apex / aorta) 
during the initial procedure. Later, the bvad can easily – under mild sedation – be 
connected on ICU. The main problem associated with a paracorporeal device is its 
suitability for short- and medium-term support only, as well as the risk of ascending 
conduit infection.
apart from multi-organ failure (MoF), the main early complications include 
bleeding and right heart failure (in case of an Lvad placement), thromboembolism 
occurs mid-term, and infection usually later. Therefore, meticulous surgical hemo-
stasis during surgery is mandatory. After the cessation of cardiopulmonary bypass, 
heparin is completely antagonised and restarted only after 6-24 hours, if there is no 
evidence of bleeding (PTT ~ 60-80 seconds). Aspirin is added after the normalisa-
tion of platelet function, and the daily dosage is adjusted (100-200 mg max.) to the 
results of aggregometry. For hospital discharge, the patient is placed on warfarin 
(iNr 2.0-4.0). in cases of aspirin resistance or embolic events under aspirin medica-
tion, clopidogrel or dipyridamol is added to achieve the adequate inhibition of the 
platelet function.
If severe right heart failure is present, the use of two paracorporeal pumps is 
recommended. After the LVAD implantation, right ventricular failure is responsible 
for approximately 30 % of early deaths. In cases with only mild to moderate right 
heart insufficiency, pharmacological intervention is sufficient. After the implanta-
tion, the LVAD flow should be increased gradually to avoid the right ventricular 
overload. additionally, the right ventricle can be stimulated by inotropes, and pul-
monary vascular resistance can be lowered specifically by the systemic application 
of PDE-5-inhibitors, prostaglandins and nitrates and/or by the inhalative application 
of prostaglandins and nitric oxide. A temporary support with a centrifugal pump is 
possible, too; however, it hinders patient mobilization.
The occurrence of neurological events depends on a patient’s condition, the anti-
coagulation regime, and the VAD system. The average risk varies between 5 and 30 
%, and it is highest during the first three months. However, asymptomatic throm-
boembolism is not infrequent, predominantly in the liver, spleen and kidney.
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vad-related infection is a major limitation of the long-term support, and it is 
responsible for approximately 20 % of the deaths after the first month after the LVAD 
implantation. Besides the highly aseptic surgery, daily careful wound dressing of 
the cannulas and driveline ports is mandatory. A proper fixation of the driveline 
closely to the skin outlet facilitates the healing and prevents the driveline infection 
as well. In case of an infection, the early onset of antibiotic therapy, as well surgical 
wound care, are imperative. In rare cases, an exchange of the VAD system or urgent 
heart transplantation remains the only option.
Results with VADs strongly depend on patient selection. Accordingly, a careful 
and individualized patient and VAD selection improve the results and lower the costs. 
The overall outcome data are best documented in the Us iNTerMacs registry. From 
June 2006 to March 2009, a total of 1,092 patients on LVAD were reported there. The 
survival rate after the primary LVAD implantation was 74 % after 12 months and 55 
% after 24 months (event death, censored at transplant or recovery). These are signifi-
cantly better results than with the survival after the RVAD, BVAD or TAH (six-month 
survival rate of approximately 50 % in all instances). The following problems/com-
plications after the VAD implantation were reported: major bleeding events; throm-
boembolism; infection; right ventricular failure on LVAD; persistent ventricular fibril-
lation on Lvad; and inadequate mobilisation possibility of the patient.
In conclusion: with the current VAD systems, good results may be obtained with 
a low complication rate and a high quality of life during support. The implantable 
and miniaturised VAD systems allow for increasing the support intervals and pav-
ing the way for destination therapy.
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Sažetak
Najbolji izbor – kako izabrati odgovarajući uređaj?
Sve veći broj pacijenata u terminalnoj fazi zatajivanja srca zahtijevaju ugradnju mehaničke 
potpore srcu i cirkulaciji, kao premoštenje do transplantacije srca ili kao destinacijska terapija. 
Odabir odgovarajućeg uređaja ovisi o kliničkom stanju pacijenta, potrebi za jednostrukom ili 
dvostrukom ventrikularnom potporom, očekivanom trajanju ugrađene potpore i mogućnostima 
institucije. Pacijentima s multi organskim zatajenjem i nejasnim neurološkim smetnjama može se 
prvo ugraditi rotacijska pumpa/ECMO, te u slučaju oporavka., parakorporalni uređaj može biti 
povezan s ranije implantiranim kanilama. Kod stabilnih pacijenata, predodređenih za ugradnju 
potpore lijevom ventriklu, moguće je ugraditi intrakorporalni uređaj druge generacije, koji do-
zvoljava slobodno kretanje 6-8 sati do punjenja baterija i podupire intervale preko jedne godine. 
Ograničenja nastaju zbog potrebe za visokim dozama antikoagulacijske terapije i pojave odre-
đenih komplikacija, posebno u prva tri mjeseca nakon implantacije (krvarenje, tromboembolija, 
infekcija, mehaničke nepravilnosti). Stopa preživljenja 12 mjeseci nakon ugradnje LVAD-a je 74% 
i 55% nakon 24 mjeseca što je značajno bolje nego preživljenje nakon ugradnje RVAD, BVAD 
or TAH.
Ključne riječi: zatajivanje srca; mehanička potpora srcu; transplantacija srca
